Skip to main content
BioCentury on BioBusiness
Feature Story

XO1's hit men

How J&J's role in advising XO1 triggered takeout of anticoagulant play

By Jennifer Rhodes, Staff Writer

Johnson & Johnson's hands-on role in the development of XO1 Ltd.'s ichorcumab and knowledge of the anticoagulant space convinced the pharma the time was right to acquire the preclinical biotech.

On March 19, J&J's Janssen Pharmaceuticals Inc. unit said it acquired the Index portfolio company for an undisclosed sum to gain its sole asset, ichorcumab. The mAb is a synthetic version of an antibody discovered in a patient that could prevent thrombosis without increasing risk of bleeding, a side effect of marketed anticoagulants.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.